The Exchange had sought clarification from NGL Fine-Chem Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is enclosed.
NGLFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE had asked NGL Fine-Chem to clarify a discrepancy in the XBRL filing of its Q4 and FY25 financial results. The company explained that the results were erroneously filed under the NON-INDAS tab instead of the INDAS tab due to an oversight, while the underlying accounts were correctly prepared as per INDAS. The filing is a procedural correction and the audited results themselves remain unchanged. The results show consolidated FY25 revenue of around Rs 36,826 lakhs (up from Rs 33,590 lakhs in FY24) and PAT of about Rs 2,112 lakhs (up from Rs 1,432 lakhs). The board has recommended a final dividend of Rs 1.75 per share, and the AGM is scheduled for August 19, 2025.
This is a technical filing error, not a financial or governance issue — shareholders should not be concerned. The actual financial performance is strong with healthy profit growth and a dividend declaration, so impact on the stock is expected to be neutral to slightly positive.